VAX March 2014
Vol. 12, No. 02 - March 2014
- Category: VAX March 2014
- Category: VAX March 2014
The East African country of Uganda has become the latest to increase the penalties for homosexual behaviors, raising strong concerns among international aid organizations, and HIV/AIDS groups in particular, that the new legal framework in the country could have devastating effects on public health efforts, in addition to violating human rights.
The Anti-Homosexuality Act, as the bill in Uganda is called, allows for life sentences for HIV-infected men who have sex with other men and criminalizes the “promotion” and “recognition” of homosexual relations by individuals and groups. This policy, signed into law by Ugandan President Yoweri Museveni on February 24, passed the Uganda Legislature with broad support from political leaders and the public.
Laws prohibiting homosexual behaviors are hardly unique—homosexual activity is prohibited in 38 of 54 countries in Africa, according to the International Lesbian and Gay Association, and according to estimates by the United Nations, in 78 countries worldwide.
Both Russia and the West African country of Nigeria have recently passed new anti-homosexuality legislation. Nigeria’s law, passed in January, carries up to 14-year prison sentences for anyone entering a same-sex union, and 10-year sentences for persons or groups that support gay-related activities or organizations. Last December, India’s Supreme Court reinstated a colonial-era law making homosexuality a crime, while Australia’s high court recently overturned laws allowing same-sex marriages.
However, the Ugandan law is particularly disconcerting to HIV/AIDS researchers as the country is a major recipient of both international research and development money. Uganda’s response to the AIDS pandemic was highly lauded internationally and was often cited as an example for other African countries. The country was one of the original recipients of the President’s Emergency Plan for AIDS Relief (PEPFAR), and is slated to receive around US$324 million in PEPFAR money this year.
The US, Norway, Denmark, Sweden, and the World Bank have already announced they are withholding or diverting some foreign aid from Uganda, and the US National Institutes of Health—the largest public provider of research funds in the world—is reportedly contemplating whether it is too risky in these countries to fund research that involves people engaging in “criminalized” behaviors, said Chris Beyrer, director of the Johns Hopkins Center for Public Health and Human Rights.
For now, it is too soon to discern just how the Anti-Homosexuality Act will impact HIV/AIDS funding in Uganda, or the long-standing research projects that have been established in the country.
Uganda’s Parliament first introduced the amended bill in 2009, but withdrew it over objections that the penalties, which then included the death penalty, were too harsh. A revised version was finally passed by the Parliament in December 2013. Initially, President Museveni declined to sign it, but changed his mind after reviewing the findings of a committee appointed by the Ugandan Health Ministry to review the scientific evidence about the causes of homosexuality. “Their unanimous conclusion was that homosexuality, contrary to my earlier thinking, was behavioural and not genetic. It was learnt and could be unlearnt,” Museveni wrote to US President Barack Obama on February 18, according to a recent article in Science magazine. However, some scientists on the 11-member committee said their findings were misrepresented, according to the Science article.
- Category: VAX March 2014
Could the same antibodies that have become the crux of vaccine research have a role in treating or even curing HIV?
The ongoing discovery of infection-fighting proteins called antibodies that can inactivate or neutralize a wide swath of different HIV strains has revolutionized the quest for a globally effective preventive HIV vaccine (see VAX Feb. 2007Primer on Understanding Neutralizing Antibodies). Since 2009 when the first wave of so-called broadly neutralizing antibodies (bNAbs) were identified, HIV prevention researchers have made multiple advances in understanding how these antibodies are able to neutralize HIV so effectively and are beginning to harness this knowledge to develop new vaccine candidates. Now teams of researchers from the HIV prevention field are demonstrating that these same broadly neutralizing antibodies may also have a therapeutic role that could possibly even advance the search for an HIV cure.
Antibodies’ immune arsenal
Antibodies are involved in a broad repertoire of immune functions that allow the body to fight off infection. They are made by B cells, a type of immune cell that is activated when exposed to a pathogen like HIV. Once activated, the B cell becomes a plasma cell that makes antibodies against a specific pathogen. Some HIV-specific antibodies are capable of neutralizing the virus by latching onto it directly. But not all antibodies are neutralizing, and in fact, both neutralizing and non-neutralizing antibodies also act in other ways. Some help other types of immune cells do their jobs. For example, antibodies can bind to cells that already are infected with virus and facilitate their destruction by other immune cells via a mechanism called antibody-dependent cellular cytotoxicity, or ADCC (see VAX Jan. 2010Primer on Understanding Antibody Functions: Beyond Neutralization). Findings from the RV144 AIDS vaccine efficacy trial that showed modest protection against HIV for the first time, indicate that the non-neutralizing antibodies induced by the vaccine candidate likely facilitated ADCC, suggesting this antibody function may play an important role.
Antibodies at work
Based on the results of RV144 and the recent discoveries around bNAbs, researchers are now widely in agreement that a preventive HIV vaccine would need to induce some type of antibody response. A handful of recent studies have also shown that antibodies may have an important role to play in treating HIV infection, even in advancing the quest for an HIV cure.
Typically, a cure involves complete banishment of a virus from a person’s body. But in the case of HIV, it is also possible that a person may have residual virus but remain unharmed, even without taking antiretroviral drugs (ARVs). In this case, the immune system is able to keep the remaining virus in check. This is often referred to as a “functional” cure.
ARV therapy prevents the spread of HIV by inhibiting various stages of HIV’s life cycle, but the drugs do not directly kill the virus or remove all virus from an infected person. As a consequence, if therapy is discontinued the virus eventually rebounds in most individuals, making treatment for HIV-infected individuals a life-long prospect. Hence researchers have been increasingly focusing on different avenues of research to cure HIV-infected individuals. One approach that has shown promise in babies is to use early and aggressive ARV treatment (see Spotlight, this issue). Other approaches involve complicated methods of teasing HIV out of its hiding places in the body and eliminating it while a person remains on ARVs. Another approach that has shown some success in animal models involves administering some of the same bNAbs that are the centerpiece of HIV vaccine research.
In 2012, researchers showed that a cocktail of bNAbs could effectively control HIV virus replication in humanized mice (genetically altered so that they have the components of a human immune system). After stopping treatment, the antibody-treated mice were able to control HIV for an even longer time than those that just received ARVs.
Last year, reports by two teams of investigators showed similar findings in monkeys using a single bNAb or multiple bNAbs in combination. In both studies, the infusion of bNAbs significantly reduced the quantity of virus in the blood. This suppression of virus lasted for weeks, as long as antibody levels were maintained. In one case, a single antibody was able to achieve the same level of virus suppression as multiple bNAbs. Researchers even observed that the antibody-treated monkeys cleared the virus faster than HIV-infected humans taking ARVs, suggesting that these potent antibodies may have a role in HIV treatment or even efforts toward a cure.
Researchers at the National Institute of Allergy and Infectious Diseases are now recruiting HIV-infected individuals for the first clinical trial to evaluate the therapeutic potential of a bNAb discovered by scientists at the Institute. This is not the first time antibodies have been tested as a treatment, but researchers are hoping for even better results using the new more potent antibodies available today.
A global blueprint for cure research laid out by leading scientists in 2012 puts antibodies front and center among strategies to control viral replication and kill already HIV-infected cells. Although cure research is in its infancy, it is a burgeoning field. And while vaccine researchers face the challenge of figuring out how to induce these powerful bNAbs via vaccination, the challenge in using these antibodies for treatment will be to engineer antibodies that are potent enough, easy enough to manufacture, and practical enough to administer to millions of HIV-infected people worldwide.
Written by Donna Rubens, PhD, Senior Writer.